• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    3/29/22 2:17:00 PM ET
    $AVAH
    $CELZ
    $IGMS
    $LIAN
    Medical/Nursing Services
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $AVAH alert in real time by email

     

    Gainers

    • IGM Biosciences (NASDAQ:IGMS) shares rose 114.8% to $32.2 during Tuesday's regular session. IGM Biosciences's stock is trading at a volume of 31.6 million shares as of 13:31 EST. This is 10213.6% of its average full-day volume over the last 100 days. The company's market cap stands at $1.0 billion. As per the press release, Q4 earnings came out today.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 62.42% to $0.33. Trading volume for China SXT Pharmaceuticals's stock is 182.4 million as of 13:31 EST. This is 2844.2% of its average full-day volume over the last 100 days. The company's market cap stands at $9.5 million.
    • PhaseBio Pharmaceuticals (NASDAQ:PHAS) shares moved upwards by 25.21% to $1.44. As of 13:31 EST, PhaseBio Pharmaceuticals's stock is trading at a volume of 495.7K, which is 157.0% of its average full-day volume over the last 100 days. The company's market cap stands at $70.1 million. As per the news, the Q4 earnings report came out 3 days ago.
    • Molecular Templates (NASDAQ:MTEM) shares increased by 24.44% to $3.36. Trading volume for Molecular Templates's stock is 334.6K as of 13:31 EST. This is 153.3% of its average full-day volume over the last 100 days. The company's market cap stands at $189.1 million. The company's, Q4 earnings came out yesterday.
    • LianBio (NASDAQ:LIAN) stock increased by 19.28% to $3.34. As of 13:31 EST, this security is trading at a volume of 1.5 million shares, making up 587.4% of its average full-day volume over the last 100 days. The company's market cap stands at $358.1 million.
    • Ontrak (NASDAQ:OTRKP) shares moved upwards by 17.15% to $9.9.

     

    Losers

    • NeoGenomics (NASDAQ:NEO) stock declined by 27.7% to $12.87 during Tuesday's regular session. As of 13:31 EST, this security is trading at a volume of 14.6 million shares, making up 1379.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.5 billion.
    • Aveanna Healthcare Hldgs (NASDAQ:AVAH) stock decreased by 26.93% to $3.94. Aveanna Healthcare Hldgs's stock is trading at a volume of 3.4 million shares as of 13:31 EST. This is 1142.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $725.3 million. The company's, Q4 earnings came out yesterday.
    • Progenity (NASDAQ:PROG) stock decreased by 24.78% to $1.21. Trading volume for Progenity's stock is 17.3 million as of 13:31 EST. This is 166.7% of its average full-day volume over the last 100 days. The company's market cap stands at $198.3 million. As per the press release, Q4 earnings came out yesterday.
    • Soleno Therapeutics (NASDAQ:SLNO) shares decreased by 23.3% to $0.22. As of 13:31 EST, this security is trading at a volume of 6.2 million shares, making up 2588.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $17.6 million.
    • Creative Medical Tech (NASDAQ:CELZ) shares decreased by 21.37% to $3.57. The current volume of 2.7 million shares is 50.1% of Creative Medical Tech's average full-day volume over the last 100 days (last updated at 13:31 EST). The market value of their outstanding shares is at $22.5 million.
    • Ocuphire Pharma (NASDAQ:OCUP) shares decreased by 20.88% to $3.36. Trading volume for this security as of 13:31 EST is 2.1 million, which is 1146.5% of its average full-day volume over the last 100 days. The company's market cap stands at $63.8 million. As per the news, the Q4 earnings report came out 3 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AVAH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVAH
    $CELZ
    $IGMS
    $LIAN

    CompanyDatePrice TargetRatingAnalyst
    Aveanna Healthcare Holdings Inc.
    $AVAH
    12/8/2025Outperform
    William Blair
    Soleno Therapeutics Inc.
    $SLNO
    11/18/2025$75.00Outperform
    Wolfe Research
    Aveanna Healthcare Holdings Inc.
    $AVAH
    11/13/2025$11.00Outperform
    BMO Capital Markets
    Soleno Therapeutics Inc.
    $SLNO
    10/7/2025$125.00Buy
    Goldman
    Aveanna Healthcare Holdings Inc.
    $AVAH
    9/18/2025$10.00Underweight → Neutral
    Analyst
    Soleno Therapeutics Inc.
    $SLNO
    8/20/2025$123.00Overweight
    Wells Fargo
    Aveanna Healthcare Holdings Inc.
    $AVAH
    8/19/2025$9.50Equal Weight → Overweight
    Barclays
    Aveanna Healthcare Holdings Inc.
    $AVAH
    8/19/2025$8.00Sell → Neutral
    UBS
    More analyst ratings

    $AVAH
    $CELZ
    $IGMS
    $LIAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Aveanna

    William Blair initiated coverage of Aveanna with a rating of Outperform

    12/8/25 8:33:04 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Wolfe Research initiated coverage on Soleno Therapeutics with a new price target

    Wolfe Research initiated coverage of Soleno Therapeutics with a rating of Outperform and set a new price target of $75.00

    11/18/25 8:27:59 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BMO Capital Markets initiated coverage on Aveanna with a new price target

    BMO Capital Markets initiated coverage of Aveanna with a rating of Outperform and set a new price target of $11.00

    11/13/25 9:12:15 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    $AVAH
    $CELZ
    $IGMS
    $LIAN
    SEC Filings

    View All

    SEC Form 8-K filed by Soleno Therapeutics Inc.

    8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

    3/16/26 9:28:28 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Aveanna Healthcare Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Aveanna Healthcare Holdings, Inc. (0001832332) (Filer)

    3/12/26 7:30:26 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Aveanna Healthcare Holdings Inc. filed SEC Form 8-K: Leadership Update

    8-K - Aveanna Healthcare Holdings, Inc. (0001832332) (Filer)

    2/27/26 4:30:28 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    $AVAH
    $CELZ
    $IGMS
    $LIAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Weil Samuel Altman

    3 - Aveanna Healthcare Holdings, Inc. (0001832332) (Issuer)

    3/18/26 5:30:07 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    CHIEF FINANCIAL OFFICER Fulk Jennifer was granted 39,200 shares (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    3/4/26 5:59:56 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Fulk Jennifer

    3 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    3/4/26 5:58:24 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AVAH
    $CELZ
    $IGMS
    $LIAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sherman Jeffrey Scott bought $112,322 worth of shares (20,000 units at $5.62), increasing direct ownership by 12% to 188,332 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:57 PM ET
    $NEO
    Precision Instruments
    Health Care

    Chief Executive Officer Zook Anthony P. bought $99,954 worth of shares (17,900 units at $5.58), increasing direct ownership by 89% to 38,066 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:25 PM ET
    $NEO
    Precision Instruments
    Health Care

    Director Kelly Michael Aaron bought $38,000 worth of shares (5,000 units at $7.60) (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    5/28/25 4:07:40 PM ET
    $NEO
    Precision Instruments
    Health Care

    $AVAH
    $CELZ
    $IGMS
    $LIAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostics Services Program (MolDX) under LCD - MolDX: Plasma-Based Genomic Profiling in Solid Tumors (L38043). This decision will enable Medicare patients to receive coverage for PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test designed to support therapy selection and clinical trial enrollment in patients with advanced solid tumors. The LBx test is performed in our CLIA-certified laboratory in California. "Securing Medicar

    3/16/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    Aveanna Healthcare Holdings Announces Agreement to Acquire Family First Homecare

    ATLANTA, March 12, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced that it has entered into an agreement to acquire Family First Holding, LLC ("Family First Homecare"). Family First Homecare is a scaled, multi-state provider of pediatric home care that primarily provides skilled Private Duty Nursing services with 27 locations in seven states including Florida, Illinois, Iowa, Pennsylvania, South Dakota, Texas, and North Carolina, where it is currently launching operations. The acquisition of Family First Homecare expands Aveanna'

    3/12/26 7:30:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse c

    2/26/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AVAH
    $CELZ
    $IGMS
    $LIAN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for RYZUMVI issued to OCUPHIRE PHARMA INC

    Submission status for OCUPHIRE PHARMA INC's drug RYZUMVI (ORIG-1) with active ingredient PHENTOLAMINE has changed to 'Approval' on 09/25/2023. Application Category: NDA, Application Number: 217064, Application Classification: Type 3 - New Dosage Form

    9/26/23 12:02:02 PM ET
    $OCUP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAH
    $CELZ
    $IGMS
    $LIAN
    Leadership Updates

    Live Leadership Updates

    View All

    Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse c

    2/26/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

    – Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 million – – Announces Chief Financial Officer transition – NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue For the fourth quarter of 2025, NeoGenomics expects to report total revenue of approximately $190 million, representing year-over-year growth of 11%. For the full-year 2025, Neo

    1/12/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. "Jack" Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service. Mr. Kenny brings to the NeoGenomics Board over three decades of diverse executive, commercial, and operational experience and a track record of success in the diagnostics and lab services businesses. He most recently served as President, Chief Executive Officer and Board Director of Meridian Bioscience, a fully i

    12/30/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $AVAH
    $CELZ
    $IGMS
    $LIAN
    Financials

    Live finance-specific insights

    View All

    Aveanna Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that the company will release its fourth quarter and full year results before the market open on Thursday, March 19, 2026, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13757396. The replay will be available until March

    2/26/26 6:30:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

    REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three and twelve months ended December 31, 2025, was $91.7 million and $190.4 million, respectively.From approval on March 26, 2025 through December 31, 2025, Soleno reports: 1,250 patien

    2/25/26 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

    Full-year revenue increased 10% to $727 million; Full-year clinical revenue grew 15%, or 13% excluding the Pathline acquisition; Successfully resolved RaDaR ST patent litigation NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its fourth-quarter and full-year results for the period ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights   Fourth quarter consolidated revenue increased 11% to $190 million; Full-year consolidated revenue increased 10% to $727 million Fourth quarter net loss decreased 36% to $10 million; Full-year net loss increased 37

    2/17/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $AVAH
    $CELZ
    $IGMS
    $LIAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/19/24 9:44:27 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

    SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

    11/18/24 9:49:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

    SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

    11/14/24 4:37:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care